AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$CRMD

CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CORMEDIX ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES Parsippany, NJ – October 19, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Admini

Original reporting
SEC EDGAR 8-K
Published Oct 19, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$CRMD
Bullish
high confidence
Mentioned
$CRMD
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRMDBullishHigh
01

Why it matters

The acceptance moves the drug closer to market, likely improving revenue prospects and stock valuation.

02

Market read

Regulatory approval pathway news for a niche biotech can trigger a short-term price rally.

03

What to watch

Potential competition from other antifungal agents and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

CorMedix Therapeutics (Nasdaq: CRMD) announced FDA acceptance for priority review of its rezafungin product for prophylaxis of invasive fungal diseases.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

FDA accepted CorMedix's supplemental NDA for REZZAYO, granting Priority Review with a Q1 2027 target.

Expected impact

upward pressure as investors price in higher chance of approval and future sales.

Evidence & confidence

First disclosure of FDA acceptance; biotech stocks typically rally on such news.

Market effects

Sector

Strengthens outlook for antifungal therapeutics and may boost peer biotech valuations.

Regional

US biotech sector may see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If FDA later requests additional data, the rally could reverse.

Key entities

  • company
    CorMedix Therapeutics

    Biopharma developing REZZAYO (rezafungin).

  • partner
    Mundipharma

    Global development partner submitting the sNDA.

  • regulator
    FDA

    U.S. Food and Drug Administration granting priority review.

Read at source← All news

Related articles

$CRMDMedAI 8/10

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

SEC EDGAR 8-K
$CRMDMed

CorMedix reports $355M cash, reaffirms 2026 revenue guidance

CorMedix (CRMD) reported $355M in cash as of September 30 and reaffirmed its 2026 revenue guidance of $325M-$345M. The CMS set a Q1 2027 Add-on payment for DefenCath at $8.32 per session, within the company's guided range. CorMedix expects the Add-on to decline in Q2 2027 but increase in Q3 and Q4, with the average rate exceeding 2x the current rate. The company plans to discuss financial results on November 12, 2026.

investing.com
$CRMDMed

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

stocktitan.net
$CRMDMedAI 8/10

CorMedix Gains FDA Priority Review For REZZAYO's Potential New Indication

CorMedix (CRMD) and Mundipharma's REZZAYO (rezafungin) received FDA Priority Review for preventing invasive fungal diseases. The sNDA is based on the Phase 3 ReSPECT study, with a target action date in Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis. If approved, CorMedix plans to start promotions in H2 2027. CRMD stock is up 0.55% in pre-market trading.

rttnews.com
$CRMDMedAI 8/10

CorMedix Wins Priority Review For REZZAYO SNDA In Fungal Disease Prevention

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO (rezafungin) to prevent fungal diseases, granting Priority Review. The application, submitted by partner Mundipharma, is based on a Phase 3 trial. The FDA set a target action date for Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis in certain patients. The stock was up 0.55% in pre-market trading.

rttnews.com